InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release. The multinational, randomized, double-blind ...

A 2-point improvement in pain based on a numeric rating scale may indicate that patients are responding to treatment for pyoderma gangrenosum. To help determine whether a patient with pyoderma ...

This population-based cohort study, conducted over a 17-year span, evaluated the association between all-cause and cause-specific mortality in 3,386 patients with pyoderma gangrenosum (PG ...

Pyoderma gangrenosum is a rare condition of unknown etiology that was described as an extraintestinal manifestation of inflammatory bowel disease in 1930. At present, there are few well-designed ...

Pyoderma Gangrenosum. ... PG is associated with other conditions in up to 75% of patients, ... from minimal trauma or irritation to the skin, debridement, graft harvest sites, stoma placement ...

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin ...

A study conducted by Lyon and colleagues involved 19 patients with varying dermatoses that were treated with sucralfate powder; 9 patients were diagnosed with erosive, fecal, or urine irritant ...

Of these patients, the researchers pinpointed 29 as having key indicators of VEXAS syndrome. All 29 of these patients were men, with a median age of 57.1 years, and 44.8% had an unknown subtype of PG.

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.; PG is a rare and debilitating autoimmune skin ...